LHDX Pengajuan SEC - Lucira Health Inc- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

CIK

1652724

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Lucira Health Inc

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

October 4, 2023	15-12G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39976 Lucira Health, Inc. (Exact name of registrant as specified
September 25, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2023 Lucira Health, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2023 Lucira Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39976 27-2491037 (State or Other Jurisdiction of Incorporation) (Commission
September 25, 2023	EX-99.2	UNITED STATES BANKRUPTCY COURT Exhibit 99.2 UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE In Re. LUCIRA HEALTH, INC., § Case No. 23-10242 § § Debtor(s) § ☐ Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 08/31/2023 Petition Date: 02/22/2023 Months Pending: 6 Industry Classification: Reporting Method: Accrual Basis Cash Basis Debtor’s F
September 25, 2023	EX-99.1	Case 23-10242-MFW Doc 652 Filed 09/19/23 Page 1 of 46 IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE In re: Chapter 11 LUCIRA HEALTH, INC.,1 Case No. 23-10242 (MFW) Debtor. Ref. Docket Nos. 511 & 628 FINDINGS OF FACT, CONCLUSIO Exhibit 99.1 Case 23-10242-MFW Doc 652 Filed 09/19/23 Page 1 of 46 IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE In re: Chapter 11 LUCIRA HEALTH, INC.,1 Case No. 23-10242 (MFW) Debtor. Ref. Docket Nos. 511 & 628 FINDINGS OF FACT, CONCLUSIONS OF LAW, AND ORDER APPROVING THE DISCLOSURE STATEMENT ON A FINAL BASIS AND CONFIRMING THE CHAPTER 11 PLAN OF LIQUIDATION FOR LUCIRA HEA
August 15, 2023	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: June 30, 2023 ☐ Transit NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: June 30, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form N-SAR ☐ For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
June 29, 2023	S-8 POS	As filed with the U.S. Securities and Exchange Commission on June 29, 2023 S-8 POS As filed with the U.S. Securities and Exchange Commission on June 29, 2023 Registration No. 333-264237 Registration No. 333-252839 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-264237 Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-252839 UNDER THE SECURITIES ACT OF
June 29, 2023	S-8 POS	As filed with the U.S. Securities and Exchange Commission on June 29, 2023 S-8 POS As filed with the U.S. Securities and Exchange Commission on June 29, 2023 Registration No. 333-264237 Registration No. 333-252839 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-264237 Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-252839 UNDER THE SECURITIES ACT OF
June 12, 2023	EX-99.2	IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE In re: LUCIRA HEALTH, INC.,1 Debtor. Chapter 11 Case No. 23-10242 (MFW) CHAPTER 11 PLAN OF LIQUIDATION FOR LUCIRA HEALTH, INC. YOUNG CONAWAY STARGATT & TAYLOR, LLP Sean M. Beach (No. EX-99.2 Exhibit 99.2 IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE In re: LUCIRA HEALTH, INC.,1 Debtor. Chapter 11 Case No. 23-10242 (MFW) CHAPTER 11 PLAN OF LIQUIDATION FOR LUCIRA HEALTH, INC. YOUNG CONAWAY STARGATT & TAYLOR, LLP Sean M. Beach (No. 4070) Ashley E. Jacobs (No. 5635) Joshua B. Brooks (No. 6765) Timothy R. Powell (No. 6894) Rodney Square 1000 N. King Street Wilm
June 12, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2023 Lucira Health, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2023 Lucira Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39976 27-2491037 (State or Other Jurisdiction of Incorporation) (Commission File N
June 12, 2023	EX-99.1	IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE In re: LUCIRA HEALTH, INC.,1 Debtor. Chapter 11 Case No. 23-10242 (MFW) DISCLOSURE STATEMENT FOR CHAPTER 11 PLAN OF LIQUIDATION FOR LUCIRA HEALTH, INC. EX-99.1 Exhibit 99.1 IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE In re: LUCIRA HEALTH, INC.,1 Debtor. Chapter 11 Case No. 23-10242 (MFW) DISCLOSURE STATEMENT FOR CHAPTER 11 PLAN OF LIQUIDATION FOR LUCIRA HEALTH, INC. YOUNG CONAWAY STARGATT & TAYLOR, LLP Sean M. Beach (No. 4070) Ashley E. Jacobs (No. 5635) Joshua B. Brooks (No. 6765) Timothy R. Powell (No. 6894) Rodney Square
May 16, 2023	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: March 31, 2023 ☐ Transi NT 10-Q 1 d453003dnt10q.htm NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: March 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on
April 24, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2023 Lucira Health, Inc UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2023 Lucira Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39976 27-2491037 (State or Other Jurisdiction of Incorporation) (Commission File
April 24, 2023	EX-2.1	AMENDMENT TO ASSET PURCHASE AGREEMENT EX-2.1 Exhibit 2.1 Execution Version AMENDMENT TO ASSET PURCHASE AGREEMENT This AMENDMENT TO ASSET PURCHASE AGREEMENT (this “Amendment”) is made and entered into as of April 18, 2023, by and between Pfizer Inc., a Delaware corporation (“Buyer”), and Lucira Health, Inc., a Delaware corporation (“Seller”). BACKGROUND WHEREAS, on February 22, 2023, Seller filed a voluntary petition for relief commenc
April 18, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2023 Lucira Health, Inc UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2023 Lucira Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39976 27-2491037 (State or Other Jurisdiction of Incorporation) (Commission File
April 18, 2023	EX-2.1	ASSET PURCHASE AGREEMENT by and between LUCIRA HEALTH, INC. PFIZER INC. dated as of April 12, 2023 EX-2.1 Exhibit 2.1 EXECUTED VERSION ASSET PURCHASE AGREEMENT by and between LUCIRA HEALTH, INC. and PFIZER INC. dated as of April 12, 2023 TABLE OF CONTENTS Page ARTICLE I PURCHASE AND SALE 1 1.1 Purchase and Sale of the Transferred Assets 1 1.2 Excluded Assets 2 1.3 Assumption of Certain Liabilities 2 1.4 Excluded Liabilities 3 1.5 Assumption/Rejection of Certain Contracts 3 ARTICLE II BANKRUPTCY
April 13, 2023	NT 10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2022 ☐ Tra NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form N-SAR ☐ For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
April 10, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2023 Lucira Health, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2023 Lucira Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39976 27-2491037 (State or Other Jurisdiction of Incorporation) (Commission File
April 5, 2023	EX-99.1	UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE In Re. LUCIRA HEALTH, INC., § Case No. 23-10242 § § Debtor(s) § ☐ Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 02/28/2023 Petition Date: 02/22/2023 Months EX-99.1 Exhibit 99.1 UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE In Re. LUCIRA HEALTH, INC., § Case No. 23-10242 § § Debtor(s) § ☐ Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 02/28/2023 Petition Date: 02/22/2023 Months Pending: 0 Industry Classification: 3 3 9 1 Reporting Method: Accrual Basis Cash Basis Debtor’s Full-Time Employees (current): 6
April 5, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2023 Lucira Health, Inc UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2023 Lucira Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39976 27-2491037 (State or Other Jurisdiction of Incorporation) (Commission File
February 27, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2023 Lucira Health, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2023 Lucira Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39976 27-2491037 (State or Other Jurisdiction of Incorporation) (Commission F
February 27, 2023	EX-99.1	LUCIRA HEALTH ANNOUNCES FDA AUTHORIZATION OF FIRST & ONLY AT-HOME COMBINATION COVID-19 & FLU TEST AND COMMENTS ON CHAPTER 11 BANKRUPTCY FILING Test Delivers Lab-Quality Performance with Results in 30 Minutes or Less – The First At-Home Test to Ever I EX-99.1 Exhibit 99.1 LUCIRA HEALTH ANNOUNCES FDA AUTHORIZATION OF FIRST & ONLY AT-HOME COMBINATION COVID-19 & FLU TEST AND COMMENTS ON CHAPTER 11 BANKRUPTCY FILING Test Delivers Lab-Quality Performance with Results in 30 Minutes or Less – The First At-Home Test to Ever Include Flu • Lab-quality results for both COVID-19 and Flu now available at home from one single test • COVID-19 and Flu have sim
February 22, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2023 Lucira Health, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2023 Lucira Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39976 27-2491037 (State or Other Jurisdiction of Incorporation) (Commission F
February 22, 2023	EX-99.1	Lucira Health to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process No debtor-in-possession financing required as the Company intends to fund operations and the sale process with available cash on hand. EX-99.1 Exhibit 99.1 Lucira Health to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process No debtor-in-possession financing required as the Company intends to fund operations and the sale process with available cash on hand. EMERYVILLE, CA, February 22, 2023 – Lucira Health, Inc. (Nasdaq: LHDX) (“Lucira Health,” “Lucira” or the “Company”), a medical technology company, annou
February 21, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2023 Lucira Health, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2023 Lucira Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39976 27-2491037 (State or Other Jurisdiction of Incorporation) (Commission F
January 13, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2023 Lucira Health, I UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2023 Lucira Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39976 27-2491037 (State or Other Jurisdiction of Incorporation) (Commission Fi
December 28, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2022 Lucira Health, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2022 Lucira Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39976 27-2491037 (State or Other Jurisdiction of Incorporation) (Commission F
December 22, 2022	SC 13D/A	LHDX / Lucira Health Inc / EPIQ Capital Group, LLC - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2(a) (Amendment No. 1)1 Lucira Health, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 54948U105 (CUSIP Number) Jed Clark Genera
December 22, 2022	EX-99	Joint Filing Agreement Joint Filing Agreement In accordance with Rule 13d-1(k) under the Securities and Exchange Act of 1934, the persons or entities named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the shares of common stock of the Issuer and further agree that this joint filing agreement be included as an exhibit to this Schedule 13D.
December 19, 2022	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2022 Lucira Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39976 27-2491037 (State or Other Jurisdiction of Incorporation) (Commission F
December 15, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2022 Lucira Health, I UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2022 Lucira Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39976 27-2491037 (State or Other Jurisdiction of Incorporation) (Commission Fi
November 14, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 Lucira Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39976 27-2491037 (State or Other Jurisdiction of Incorporation) (Commission F
November 14, 2022	EX-99.1	Lucira Health Announces Third Quarter 2022 Results and Provides Business Updates Exhibit 99.1 Lucira Health Announces Third Quarter 2022 Results and Provides Business Updates EMERYVILLE, Calif. – November 14, 2022 – Lucira Health, Inc. (Nasdaq: LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, today reported financial results for the third
November 14, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39976 Lucir
November 14, 2022	EX-10.1	First Amendment to Loan and Security Agreement, dated March 2, 2022, by and between the Registrant, Hercules Capital Inc., and Silicon Valley Bank. EXHIBIT 10.1 FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (this ?Amendment?), dated as of March 2, 2022 (the ?Amendment Effective Date?), is entered into by and among LUCIRA HEALTH, INC., a Delaware corporation, and each of its Subsidiaries joined hereafter from time to time pursuant to Section 7.13 of the Loan and Security Agreement (hereinaft
November 1, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2022 Lucira Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39976 27-2491037 (State or Other Jurisdiction of Incorporation) (Commission Fi
October 26, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20, 2022 Lucira Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39976 27-2491037 (State or Other Jurisdiction of Incorporation) (Commission Fi
September 22, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2022 Lucira Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39976 27-2491037 (State or Other Jurisdiction of Incorporation) (Commission
August 15, 2022	EX-10.1	Second Amendment to Loan and Security Agreement, dated June 15, 2022, by and between the Registrant, Hercules Capital Inc. and Silicon Valley Bank EXHIBIT 10.1 SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (this ?Amendment?), dated as of June 15, 2022 (the ?Amendment Effective Date?), is entered into by and among LUCIRA HEALTH, INC., a Delaware corporation, and each of its Subsidiaries joined hereafter from time to time pursuant to Section 7.13 of the Loan and Security Agreement (hereina
August 15, 2022	EX-99.1	Lucira Health Announces Second Quarter 2022 Results and Provides Business Updates Exhibit 99.1 Lucira Health Announces Second Quarter 2022 Results and Provides Business Updates EMERYVILLE, Calif. ? August 15, 2022 ? Lucira Health, Inc. (Nasdaq: LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, today reported financial results for the second
August 15, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39976 Lucira Health, Inc.
August 15, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2022 Lucira Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39976 27-2491037 (State or Other Jurisdiction of Incorporation) (Commission Fil
June 2, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 01, 2022 Lucira Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39976 27-2491037 (State or Other Jurisdiction of Incorporation) (Commission File
May 16, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39976 Lucira Health, Inc.
May 16, 2022	EX-10.2	AGENT: EXHIBIT 10.2 FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (this ?Amendment?), dated as of March 2, 2022 (the ?Amendment Effective Date?), is entered into by and among LUCIRA HEALTH, INC., a Delaware corporation, and each of its Subsidiaries joined hereafter from time to time pursuant to Section 7.13 of the Loan and Security Agreement (hereinaft
May 12, 2022	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 Lucira Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39976 27-2491037 (State or other jurisdiction of incorporation) (Commission File N
May 12, 2022	EX-99.1	Lucira Health Announces First Quarter 2022 Results and Business Update Exhibit 99.1 Lucira Health Announces First Quarter 2022 Results and Business Update EMERYVILLE, Calif. ? May 12, 2022 ? Lucira Health, Inc. (Nasdaq: LHDX) (?Lucira Health,? ?Lucira? or the ?Company?), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, today reported financial results and provided business updates
April 20, 2022	DEF 14A	SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) TABLE OF CONTENTS SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 20, 2022	DEFA14A	SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 11, 2022	EX-99.7	Forms of restricted stock unit grant notice and award agreement under the Lucira Health, Inc. 2022 Inducement Plan. Exhibit 99.7 LUCIRA HEALTH, INC. RSU AWARD GRANT NOTICE (2022 INDUCEMENT PLAN) Lucira Health, Inc. (the ?Company?) has awarded to you (the ?Participant?) the number of restricted stock units specified and on the terms set forth below (the ?RSU Award?). Your RSU Award is subject to all of the terms and conditions as set forth herein and in the Company?s 2022 Inducement Plan (the ?Plan?) and the Awa
April 11, 2022	EX-99.6	Forms of grant notice, stock option agreement and notice of exercise under the Lucira Health, Inc. 2022 Inducement Plan. Exhibit 99.6 LUCIRA HEALTH, INC. 2022 INDUCEMENT PLAN STOCK OPTION AGREEMENT As reflected by your Stock Option Grant Notice (?Grant Notice?) Lucira Health, Inc. (the ?Company?) has granted you an option under its 2022 Inducement Plan (the ?Plan?) to purchase a number of shares of Common Stock at the exercise price indicated in your Grant Notice (the ?Option?). This Option is granted in compliance
April 11, 2022	S-8	Power of Attorney (included on the signature page of this registration statement). S-8 As filed with the U.S. Securities and Exchange Commission on April 11, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Lucira Health, Inc. (Exact name of registrant as specified in its charter) Delaware 27-2491037 (State or other jurisdiction of incorporation or organization) (I.
April 11, 2022	EX-99.5	Lucira Health, Inc. 2022 Inducement Plan. Exhibit 99.5 LUCIRA HEALTH, INC. 2022 INDUCEMENT PLAN ADOPTED BY THE BOARD OF DIRECTORS: APRIL 6, 2022 TABLE OF CONTENTS Page 1. GENERAL 1 2. SHARES SUBJECT TO THE PLAN 1 3. ELIGIBILITY AND LIMITATIONS 2 4. OPTIONS AND STOCK APPRECIATION RIGHTS 2 5. AWARDS OTHER THAN OPTIONS AND STOCK APPRECIATION RIGHTS 6 6. ADJUSTMENTS UPON CHANGES IN COMMON STOCK; OTHER CORPORATE EVENTS 8 7. ADMINISTRATION 10 8
April 11, 2022	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Lucira Health, Inc.
March 31, 2022	EX-10.24	Amendment #1 to Distribution Agreement, dated December 21, 2021, by and between the registrant and Switch Health Solutions Inc. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [****], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.
March 31, 2022	EX-10.25	Loan and Security Agreement, dated February 4, 2022, by and between the registrant, Hercules Capital, Inc. and Silicon Valley Bank. Exhibit 10.25 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT is made and dated as of February 4, 2022 and is entered into by and among LUCIRA HEALTH, INC., a Delaware corporation, and each of its Subsidiaries joined hereafter from time to time pursuant to Section 7.13 hereof (hereinafter collectively referred to as the ?Borrower?), HERCULES CAPITAL, INC., a Maryland corporation (?Her
March 31, 2022	EX-4.4	Warrant to Purchase Stock, dated February 4, 2022, by and between the registrant and Silicon Valley Bank Exhibit 4.4 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 6.3 AND 6.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTAN
March 31, 2022	EX-4.5	Warrant Agreement, dated February 4, 2022, by and between the registrant and Hercules Capital, Inc. Exhibit 4.5 THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR ANY STATE SECURITIES LAWS, AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR, SUBJECT TO SECTION 11 HEREOF, AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUNS
March 31, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39976 Lucira Health,
March 31, 2022	EX-10.23	Distribution Agreement, dated July 14, 2021, by and between the registrant and Switch Health Solutions Inc. Confidential ? [**] [] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [**], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.
March 14, 2022	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2022 Lucira Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39976 27-2491037 (State or other jurisdiction of incorporation) (Commission File
March 10, 2022	EX-99.1	Lucira Health Announces Fourth Quarter and Full Year 2021 Results and Reaffirms 2022 Financial Outlook Exhibit 99.1 Lucira Health Announces Fourth Quarter and Full Year 2021 Results and Reaffirms 2022 Financial Outlook EMERYVILLE, Calif. ? March 10, 2022 ? Lucira Health, Inc. (Nasdaq: LHDX) (?Lucira Health,? ?Lucira? or the ?Company?), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today reported financial
March 10, 2022	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2022 Lucira Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39976 27-2491037 (State or other jurisdiction of incorporation) (Commission File
February 14, 2022	EX-99.1	JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement.
February 14, 2022	SC 13G	LHDX / Lucira Health Inc / Eclipse GP III, LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* LUCIRA HEALTH, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 54948U105 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule
February 8, 2022	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2022 Lucira Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39976 27-2491037 (State or other jurisdiction of incorporation) (Commission Fi
February 8, 2022	EX-99.1	Lucira Health Secures Debt Facility of Up to $80 Million from Hercules Capital and Silicon Valley Bank Exhibit 99.1 Lucira Health Secures Debt Facility of Up to $80 Million from Hercules Capital and Silicon Valley Bank EMERYVILLE, CA, February 8, 2022 (GLOBE NEWSWIRE) ? Lucira Health, Inc. (?Lucira Health? or ?Lucira?) (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that on F
January 10, 2022	EX-99.1	Lucira Health Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2021 and Provides Business Update Exhibit 99.1 Lucira Health Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2021 and Provides Business Update EMERYVILLE, CA, January 10, 2022 (GLOBE NEWSWIRE) ? Lucira Health, Inc. (?Lucira?) (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced preliminary re
January 10, 2022	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 Lucira Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39976 27-2491037 (State or other jurisdiction of incorporation) (Commission Fi
December 29, 2021	EX-99.1	Lucira Health and Co-Defend/Co-Protect Announce Expanded Partnership for 2022 Exhibit 99.1 Lucira Health and Co-Defend/Co-Protect Announce Expanded Partnership for 2022 ? Lucira is the only EUA authorized at-home self-test kit that delivers PCR-quality accuracy and early detectability in a single-use test kit with results in 30 minutes ? Co-Defend and Co-Protect are leading providers of customized health & safety solutions, and testing & advisory services to Entertainment,
December 29, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2021 Lucira Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39976 27-2491037 (State or other jurisdiction of incorporation) (Commission F
December 23, 2021	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2021 Lucira Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39976 27-2491037 (State or other jurisdiction of incorporation) (Commission F
December 22, 2021	EX-99.1	Lucira Health Announces Expanded Partnership with Switch Health to Increase Canadians’ Access to At-Home Molecular COVID-19 Tests Exhibit 99.1 Lucira Health Announces Expanded Partnership with Switch Health to Increase Canadians? Access to At-Home Molecular COVID-19 Tests ? Lucira?s tests are the only available at-home self-test kits that deliver PCR-quality accuracy and early detectability in a single-use test kit with results in 30 minutes ? Current surge of COVID-19 cases caused by the Omicron variant highlights the need
December 22, 2021	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2021 Lucira Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39976 27-2491037 (State or other jurisdiction of incorporation) (Commission F
December 21, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2021 Lucira Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39976 27-2491037 (State or other jurisdiction of incorporation) (Commission F
November 12, 2021	EX-99.1	Lucira Health Announces Third Quarter 2021 Financial Results and Provides Business Update Exhibit 99.1 Lucira Health Announces Third Quarter 2021 Financial Results and Provides Business Update EMERYVILLE, Calif. ? November 11, 2021 ? Lucira Health, Inc. (Nasdaq: LHDX) (?Lucira Health,? ?Lucira? or the ?Company?), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today reported financial results f
November 12, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39976 Lucira Health, Inc.
November 12, 2021	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2021 Lucira Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39976 27-2491037 (State or other jurisdiction of incorporation) (Commission F
November 12, 2021	EX-10.3	Employment Agreement, dated as of August 1, 2021, by and between Lucira Health, Inc. and Ghazi Kashmolah Exhibit 10.3 August 1, 2021 Ghazi Kashmolah Re:Employment Agreement Dear Ghazi: On behalf of Lucira Health, Inc. (the ?Company?), I am pleased to offer you employment at the Company on the terms set forth in this offer letter agreement (the ?Agreement?). As discussed, the terms of this Agreement govern with respect to your employment, which shall commence no later than August 16, 2021 (such actual
November 12, 2021	EX-99.2	Lucira Health, Inc. Exhibit 99.2 Lucira Health, Inc. Q3 2021 Earnings Conference Call November 11, 2021, 4:30 PM ET OPERATOR: Good afternoon, ladies, and gentlemen, and welcome to the Lucira Health third quarter earnings conference call. At this time, all participants are in listen-only mode. A question-and-answer session will follow the formal presentation. As a reminder, this conference is being recorded. I would n
November 12, 2021	EX-10.4	Lucira Health, Inc. 2021 Annual Incentive Plan Exhibit 10.4 Lucira Health, Inc. 2021 Annual Incentive Plan Purpose This Lucira Health, Inc. 2021 Annual Incentive Plan (?Plan?) is designed to provide an effective means to motivate, compensate, and retain eligible Lucira Health, Inc. (the ?Company?) employees through the payment of annual cash bonuses based on the achievement of corporate performance objectives during a calendar year (?Plan Year
October 8, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 8, 2021 Lucira Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39976 27-2491037 (State or other jurisdiction of incorporation) (Commission Fil
October 8, 2021	EX-99.1	LUCIRA™ HEALTH Provides Statement on Copan’s Recall of its FLOQSwabs Exhibit 99.1 LUCIRA? HEALTH Provides Statement on Copan?s Recall of its FLOQSwabs EMERYVILLE, CA, October 8, 2021 ? Lucira Health, Inc. (?Lucira Health? or ?Lucira?) (NASDAQ: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today commented on the recent recall of the FLOQSwabs by supply partner Copan
September 20, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2021 Lucira Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39976 27-2491037 (State or other jurisdiction of incorporation) (Commission
September 20, 2021	EX-10.1	Employment Agreement, dated as of August 30, 2021, by and between Lucira Health, Inc. and Tony Allen Exhibit 10.1 LUCIRA HEALTH, INC. August 30, 2021 Tony Allen Re:Employment Agreement Dear Tony: On behalf of Lucira Health, Inc. (the ?Company?), I am pleased to offer you employment at the Company on the terms set forth in this offer letter agreement (the ?Agreement?). As discussed, the terms of this Agreement govern with respect to your employment, which shall commence no later than September 20,
August 27, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2021 Lucira Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39976 27-2491037 (State or other jurisdiction of incorporation) (Commission Fil
August 27, 2021	EX-10.1	Separation Agreement, dated as of August 27, 2021, by and between Lucira Health, Inc. and Kelly Lewis Brezoczky Exhibit 10.1 August 27, 2021 Ms. Kelly Lewis Brezoczky Re: Separation Agreement Dear Kelly: This letter sets forth the substance of the separation agreement (the “Agreement”) that Lucira Health, Inc. (the “Company”) is offering to you to aid in your employment transition. 1. SEPARATION DATE. Your last day of work with the Company and your employment separation date will be September 3, 2021 (the “
August 13, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39976 Lucira Health, Inc.
August 13, 2021	EX-10.1	Employment Agreement, dated as of May 10, 2021, by and between the registrant and Kevin Collins. Exhibit 10.1 LUCIRA HEALTH, INC. Kevin Collins May 6, 2021 Dear Kevin, On behalf of Lucira Health Inc. (the ?Company?), it is my pleasure to offer you employment beginning on May 27, 2021 (the ?Start Date?). This letter shall serve to confirm the terms of your employment with the Company. If the terms below are acceptable to you, please sign this confirmation letter where indicated and return it t
August 12, 2021	EX-99.1	Lucira Health Announces Second Quarter 2021 Financial Results Exhibit 99.1 Lucira Health Announces Second Quarter 2021 Financial Results EMERYVILLE, Calif. ? August 12, 2021 ? Lucira Health, Inc. (Nasdaq: LHDX) (?Lucira Health,? ?Lucira? or the ?Company?), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today reported financial results for the second quarter ended Ju
August 12, 2021	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 Lucira Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39976 27-2491037 (State or other jurisdiction of incorporation) (Commission Fil
July 27, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2021 Lucira Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39976 27-2491037 (State or other jurisdiction of incorporation) (Commission File
July 16, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8-K 1 d180487d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2021 Lucira Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39976 27-2491037 (State or other jurisdiction of incorpo
May 28, 2021	8-K	Financial Statements and Exhibits, Other Events 8-K 1 lhdx-8k20210528.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2021 Lucira Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39976 27-2491037 (State or other jurisdiction of inc
May 28, 2021	EX-99.1	LUCIRA™ HEALTH Hires Chief Revenue Officer Kevin Collins Appointment expands Lucria’s management team with medtech veteran Exhibit 99.1 LUCIRA? HEALTH Hires Chief Revenue Officer Kevin Collins Appointment expands Lucria?s management team with medtech veteran EMERYVILLE, CA. ? May 28, 2021 - Lucira Health, Inc. (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced medtech veteran Kevin Collins has join
May 27, 2021	EX-99.1	Lucira Health is a medical technology company focused on the development and commercialization of transformative and innovative infectious EX-99.1 2 lhdx-ex9916.htm EX-99.1 Exhibit 99.1 Lucira Health to Participate in William Blair 41st Annual Growth Stock Conference May 25, 2021 EMERYVILLE, Calif., May 25, 2021 (GLOBE NEWSWIRE) - Lucira Health, Inc. (“Lucira Health” or “Lucira”) (NASDAQ: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits,
May 27, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 lhdx-8k20210525.htm 8-K WB PR 5-27-21 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2021 Lucira Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39976 27-2491037 (State or other juris
May 18, 2021	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2021 Lucira Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39976 27-2491037 (State or other jurisdiction of incorporation) (Commission File N
May 18, 2021	EX-99.1	LUCIRA HEALTH, INC. Exhibit 99.1 Lucira Health Announces First Quarter 2021 Financial Results May 13, 2021 EMERYVILLE, Calif, May 13, 2021 (GLOBE NEWSWIRE) - Lucira Health, Inc. ("Lucira Health," "Lucira" or the "Company") (NASDAQ: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today reported financial results for the
May 17, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39976 Lucira Health, Inc.
April 13, 2021	EX-99.1	FDA Authorizes First Single-Use, PCR quality Over The Counter (OTC) LUCIRA CHECK IT™ COVID-19 At-Home Test. Available Now. Reports Preliminary 2021 First Quarter Revenue and Business Update EX-99.1 2 lhdx-ex9916.htm EX-99.1 Exhibit 99.1 FDA Authorizes First Single-Use, PCR quality Over The Counter (OTC) LUCIRA CHECK IT™ COVID-19 At-Home Test. Available Now. Reports Preliminary 2021 First Quarter Revenue and Business Update EMERYVILLE, CA. – April 12, 2021 - Lucira Health, Inc. (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of transformat
April 13, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2021 Lucira Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39976 27-2491037 (State or other jurisdiction of incorporation) (Commission File
March 31, 2021	10-K	Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39976 Lucira Health,
March 31, 2021	EX-4.3	Description of Common Stock. Exhibit 4.3 DESCRIPTION OF COMMON STOCK General The following description summarizes the terms of the common stock of Lucira Health, Inc., or we, our or us. Because it is only a summary, it does not contain all the information that may be important to you. For a complete description of the matters set forth in this ?Description of Common Stock,? you should refer to our amended and restated certifi
February 12, 2021	SC 13D	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No.__)1 L UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No.)1 Lucira Health, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 54948U105 (CUSIP Number) Jed Clark General
February 12, 2021	EX-99	Joint Filing Agreement EX-99 2 99.1.htm 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k) under the Securities and Exchange Act of 1934, the persons or entities named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the shares of common stock of the Issuer and further agree that this joint filing agreement be included as an
February 12, 2021	EX-99	FORM OF LOCK-UP AGREEMENT EX-99 3 99.2.htm 99.2 FORM OF LOCK-UP AGREEMENT (Date) BofA Securities, Inc. William Blair & Company, L.L.C. as Representatives of the several Underwriters to be named in the within-mentioned Underwriting Agreement c/o BofA Securities, Inc. One Bryant Park New York, New York 10036 c/o William Blair & Company, L.L.C. The William Blair Building 150 North Riverside Plaza Chicago, Illinois 60606 Re: P
February 9, 2021	EX-3.2	Amended and Restated Bylaws of Lucira Health, Inc. EX-3.2 3 d941835dex32.htm EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF LUCIRA HEALTH, INC. (A DELAWARE CORPORATION) TABLE OF CONTENTS PAGE ARTICLE I OFFICES 1 Section 1. Registered Office 1 Section 2. Other Offices 1 ARTICLE II CORPORATE SEAL 1 Section 3. Corporate Seal 1 ARTICLE III STOCKHOLDERS’ MEETINGS 1 Section 4. Place of Meetings 1 Section 5. Annual Meetings. 1 Section 6. Special Meeti
February 9, 2021	EX-3.1	Amended and Restated Certificate of Incorporation of Lucira Health, Inc. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF LUCIRA HEALTH, INC. Erik T. Engelson hereby certifies that: ONE: The name of this corporation is Lucira Health, Inc., and the original Certificate of Incorporation of this corporation was filed with the Secretary of State of the State of Delaware on February 20, 2013 under the name DiAssess Inc. TWO: He is the duly elected and acting
February 9, 2021	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2021 Lucira Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39976 27-2491037 (State or other jurisdiction of incorporation) (Commissio
February 8, 2021	424B4	9,000,000 Shares Common Stock 424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration Nos. 333-252164 and 333-252760 P R O S P E C T U S 9,000,000 Shares Common Stock This is Lucira Health, Inc.’s initial public offering. We are selling 9,000,000 shares of our common stock. The public offering price for our common stock is $17.00 per share. Prior to this offering, there has been no public market for our common st
February 8, 2021	S-8	- S-8 S-8 As filed with the U.S. Securities and Exchange Commission on February 8, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Lucira Health, Inc. (Exact name of registrant as specified in its charter) Delaware 27-2491037 (State or other jurisdiction of incorporation or organization) (
February 4, 2021	S-1MEF	- S-1MEF S-1MEF As filed with the U.S. Securities and Exchange Commission on February 4, 2021. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Lucira Health, Inc. (Exact name of registrant as specified in its charter) Delaware 2835 27-2491037 (State or other jurisdiction of incorporation or organi
February 2, 2021	CORRESP	- LUCIRA HEALTH, INC. 1412 62nd Street Emeryville, California 94608 February 2, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Courtney Lindsay Mary Beth Breslin Eric Atallah Angela Connell Re: Lucira Health, Inc. Registration Statement on Form S-1, as amended (File No. 333-252164) Request for Acceleration of Eff
February 2, 2021	CORRESP	- CORRESP 1 filename1.htm February 2, 2021 U.S. Securities and Exchange Commission Office of Life Sciences Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Courtney Lindsay Mary Beth Breslin Eric Atallah Angela Connell Re: Lucira Health, Inc. Registration Statement on Form S-1, as amended File No. 333-252164 Ladies and Gentlemen: In connection with the above-referenced
February 1, 2021	EX-10.19	Employment Agreement, dated as of January 26, 2021, by and between the registrant and Hansgregory Charles Hartmann. EX-10.19 Exhibit 10.19 LUCIRA HEALTH, INC. January 18, 2021 Hansgregory Charles Hartmann Re: Employment Agreement Dear Hans: On behalf of LUCIRA HEALTH, INC. (the “Company”), it is my pleasure to offer you the position of Chief Operating Officer. The terms of your new employment are set forth below in this employment agreement (the “Agreement”). 1. EMPLOYMENT BY THE COMPANY. (a) Start Date and Pos
February 1, 2021	EX-10.4	Lucira Health, Inc. 2021 Equity Incentive Plan. EX-10.4 Exhibit 10.4 LUCIRA HEALTH, INC. 2021 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: JANUARY 28, 2021 APPROVED BY THE STOCKHOLDERS: JANUARY 28, 2021 TABLE OF CONTENTS Page 1. GENERAL. 1 2. SHARES SUBJECT TO THE PLAN. 1 3. ELIGIBILITY AND LIMITATIONS. 2 4. OPTIONS AND STOCK APPRECIATION RIGHTS. 3 5. AWARDS OTHER THAN OPTIONS AND STOCK APPRECIATION RIGHTS. 5 6. ADJUSTMENTS UPON CHA
February 1, 2021	S-1/A	- AMENDMENT NO. 1 TO FORM S-1 Amendment No. 1 to Form S-1 Table of Contents As filed with the U.S. Securities and Exchange Commission on February 1, 2021. Registration No. 333-252164 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Lucira Health, Inc. (Exact name of registrant as specified in its charter) Delaware 2835 27
February 1, 2021	8-A12B	Form 8-A 8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Lucira Health, Inc. (Exact name of registrant as specified in its charter) Delaware 27-2491037 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification
February 1, 2021	EX-1.1	Form of Underwriting Agreement. EX-1.1 Exhibit 1.1 LUCIRA HEALTH, INC. (a Delaware corporation) [●] Shares of Common Stock UNDERWRITING AGREEMENT Dated: [●], 2021 LUCIRA HEALTH, INC. (a Delaware corporation) [●] Shares of Common Stock UNDERWRITING AGREEMENT [●], 2021 BofA Securities, Inc. William Blair & Company, L.L.C. as Representatives of the several Underwriters c/o BofA Securities, Inc. One Bryant Park New York, New York 10
February 1, 2021	EX-10.8	Lucira Health, Inc. 2021 Employee Stock Purchase Plan EX-10.8 9 d19221dex108.htm EX-10.8 EXHIBIT 10.8 LUCIRA HEALTH, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: JANUARY 28, 2021 APPROVED BY THE STOCKHOLDERS: JANUARY 28, 2021 1. GENERAL (a) Purpose. The Company, by means of the Plan, seeks to retain the services of such Employees, to secure and retain the services of Employees and to provide incentives for such persons to
February 1, 2021	EX-10.7	Forms of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the Lucira Health, Inc. 2021 Equity Incentive Plan. EX-10.7 8 d19221dex107.htm EX-10.7 Exhibit 10.7 [Mandatory Sell to Cover for Withholding Taxes] LUCIRA HEALTH, INC. RSU AWARD GRANT NOTICE (2021 EQUITY INCENTIVE PLAN) Lucira Health, Inc. (the “Company”) has awarded to you (the “Participant”) the number of restricted stock units specified and on the terms set forth below in consideration of your services (the “RSU Award”). Your RSU Award is subjec
February 1, 2021	EX-3.1	Amended and Restated Certificate of Incorporation of the registrant, as currently in effect. EX-3.1 Exhibit 3.1 FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF LUCIRA HEALTH, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Lucira Health, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES HEREBY CERTIFY: 1. Th
February 1, 2021	EX-10.6	Forms of Option Agreement, Stock Option Grant Notice and Notice of Exercise under the Lucira Health, Inc. 2021 Equity Incentive Plan. EX-10.6 Exhibit 10.6 LUCIRA HEALTH, INC. 2021 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT As reflected by your Stock Option Grant Notice (“Grant Notice”) Lucira Health, Inc. (the “Company”) has granted you an option under its 2021 Equity Incentive Plan (the “Plan”) to purchase a number of shares of Common Stock at the exercise price indicated in your Grant Notice (the “Option”). Capitalized terms
February 1, 2021	EX-4.1	Form of common stock certificate EX-4.1 Exhibit 4.1 LUCIRA HEALTH NUMBER LH INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE SHARES CUSIP 54948U 10 5 SEE REVERSE FOR CERTAIN DEFINITIONS AND LEGENDS This certifies that is the record holder of FULLY PAID AND NONASSESSABLE SHARES OF COMMON STOCK, $0.001 PAR VALUE PER SHARE, OF LUCIRA HEALTH, INC. transferable on the books of the Corporation in person or by duly authorized attorn
January 25, 2021	CORRESP	- Josh Seidenfeld +1 650 843 5862 [email protected] VIA EDGAR FOIA Confidential Treatment Request Confidential Treatment Requested by Lucira Health, Inc. in connection with its Registration Statement on Form S-1 (File No. 333-252164) January 25, 2021 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Courtney Lindsay Mary Be
January 15, 2021	EX-10.14	Amended and Restated Employment Agreement, dated as of January 14, 2021, by and between the registrant and Erik T. Engelson. EX-10.14 Exhibit 10.14 LUCIRA HEALTH, INC. January 13, 2021 Erik T. Engelson Lucira Health, Inc. 1412 62nd Street Emeryville, CA 94608 Re: Amended and Restated Employment Agreement Dear Erik: You are currently employed by LUCIRA HEALTH, INC. (the “Company”) under the terms of an offer letter between you and the Company dated February 5, 2019 (the “Offer Letter”). The Company is amending and restat
January 15, 2021	S-1	Power of Attorney (included on signature page to this registration statement). S-1 Table of Contents As filed with the U.S. Securities and Exchange Commission on January 15, 2021. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Lucira Health, Inc. (Exact name of registrant as specified in its charter) Delaware 2835 27-2491037 (State or other jurisdiction of incorpor
January 15, 2021	EX-10.11	Lease Agreement, dated January 30, 2015, by and between the registrant and Hollis General Partnership, as amended. EX-10.11 Exhibit 10.11 LEASE BETWEEN HOLLIS GENERAL PARTNERSHIP (LANDLORD) AND DIASSESS, INC. (TENANT) HOLLIS GENERAL PROJECT Emeryville, California OFFICE LEASE ARTICLE 1 BASIC LEASE PROVISIONS 1.1 BASIC LEASE PROVISIONS In the event of any conflict between these Basic Lease Provisions and any other Lease provision, such other Lease provision shall control. (1) BUILDING AND ADDRESS: 1412 62nd Str
January 15, 2021	EX-10.18	Amended and Restated Employment Agreement, dated as of January 14, 2021, by and between the registrant and Tamanna Prashar. EX-10.18 Exhibit 10.18 LUCIRA HEALTH, INC. January 13, 2021 Tamanna Prashar Lucira Health, Inc. 1412 62nd Street Emeryville, CA 94608 Re: Amended and Restated Employment Agreement Dear Tamanna: You are currently employed by LUCIRA HEALTH, INC. (the “Company”) under the terms of an offer letter between you and the Company dated June 7, 2019, including the amended employment terms letter between you
January 15, 2021	EX-3.2	Form of Amended and Restated Certificate of Incorporation of the Registrant, that will be in effect immediately following the closing of the Registrant’s initial public offering of the Registrant’s Common Stock. EX-3.2 Exhibit 3.2 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF LUCIRA HEALTH, INC. Erik T. Engelson hereby certifies that: ONE: The name of this corporation is Lucira Health, Inc., and the original Certificate of Incorporation of this corporation was filed with the Secretary of State of the State of Delaware on February 20, 2013 under the name DiAssess Inc. TWO: He is the duly elected and
January 15, 2021	EX-3.4	Form of Amended and Restated Bylaws of the registrant, that will be in effect immediately prior to the closing of the Registrant’s initial public offering of the Registrant’s Common Stock. EX-3.4 Exhibit 3.4 AMENDED AND RESTATED BYLAWS OF LUCIRA HEALTH, INC. (A DELAWARE CORPORATION) TABLE OF CONTENTS PAGE ARTICLE I OFFICES 1 Section 1. Registered Office 1 Section 2. Other Offices 1 ARTICLE II CORPORATE SEAL 1 Section 3. Corporate Seal 1 ARTICLE III STOCKHOLDERS’ MEETINGS 1 Section 4. Place of Meetings 1 Section 5. Annual Meetings. 1 Section 6. Special Meetings. 5 Section 7. Notice o
January 15, 2021	EX-4.1	Form of common stock certificate of the registrant. EX-4.1 Exhibit 4.1 LH INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE CUSIP XXXXXX XX X SEE REVERSE FOR CERTAIN DEFINITIONS AND LEGENDS This certifies that is the record holder of FULLY PAID AND NONASSESSABLE SHARES OF COMMON STOCK, $0.001 PAR VALUE PER SHARE, OF Lucira Health, Inc. transferable on the books of the Corporation in person or by duly authorized attorney upon surrender of this Ce
January 15, 2021	EX-10.10	Form of Indemnification Agreement, by and between the registrant and each of its directors and executive officers. EX-10.10 Exhibit 10.10 INDEMNITY AGREEMENT THIS INDEMNITY AGREEMENT (this “Agreement”) dated as of , is made by and between LUCRIA HEALTH, INC., a Delaware corporation (the “Company” or “Lucira” ), and (“Indemnitee” ). RECITALS A. The Company desires to attract and retain the services of highly qualified individuals as directors, officers, employees and agents. B. The Company’s amended and restate
January 15, 2021	EX-3.3	Amended and Restated Bylaws of the registrant, as currently in effect. EX-3.3 Exhibit 3.3 AMENDED AND RESTATED BYLAWS OF LUCIRA HEALTH, INC. (A DELAWARE CORPORATION) ARTICLE I OFFICES Section 1. Registered Office. The registered office of the corporation in the State of Delaware shall be 1209 Orange Street, City of Wilmington, County of New Castle, 19801. Section 2. Other Offices. The corporation shall also have and maintain an office or principal place of business a
January 15, 2021	EX-3.1	Amended and Restated Certificate of Incorporation of the registrant, as currently in effect. EX-3.1 Exhibit 3.1 FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF LUCIRA HEALTH, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Lucira Health, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES HEREBY CERTIFY: 1. T
January 15, 2021	EX-10.12	Manufacturing Services Agreement, dated September 10, 2020, by and between the registrant and Jabil Inc. EX-10.12 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [****], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Exhibit 10.12 CONFIDENTIAL – EXECUTION VERSION MANUFACTURING SERVICES AGREEMENT between JABIL INC., and LUCIRA HEALTH INC. INDEX 1. Definitions 1 2. List of Schedules 5 3. Forecasts 5 3.1 Forecast
January 15, 2021	EX-10.16	Amended and Restated Employment Agreement, dated as of January 14, 2021, by and between the registrant and Kelly Lewis Brezoczky. EX-10.16 Exhibit 10.16 LUCIRA HEALTH, INC. January 13, 2021 Kelly Lewis Brezoczky Lucira Health, Inc. 1412 62nd Street Emeryville, CA 94608 Re: Amended and Restated Employment Agreement Dear Kelly: You are currently employed by LUCIRA HEALTH, INC. (the “Company”) under the terms of an offer letter between you and the Company dated April 10, 2020 (the “Offer Letter”). The Company is amending and re
January 15, 2021	CORRESP	- Josh Seidenfeld +1 650 843 5862 [email protected] January 15, 2021 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Eric Atallah Angela Connell Courtney Lindsay Mary Beth Breslin Re: Lucira Health, Inc. Amendment No. 1 to Draft Registration Statement on Form S-1 Submitted December 23, 2020 CIK No. 0001652724 Ladies and Gen
January 15, 2021	EX-4.2	Amended and Restated Investor Rights Agreement, dated August 7, 2020, by and among Lucira Health, Inc. and the investors listed on Schedule A thereto EX-4.2 Exhibit 4.2 LUCIRA HEALTH, INC. AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT THIS AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (this “Agreement”), is made as of the 7th day of August, 2020, by and among Lucira Health, Inc., a Delaware corporation (the “Company”), each of the investors listed on SCHEDULE A hereto, each of which is referred to in this Agreement as an “Investor”, and any A
January 15, 2021	EX-10.2	Forms of Option Agreement, Stock Option Grant Notice and Notice of Exercise under the Lucira Health, Inc. 2014 Equity Incentive Plan, as amended. EX-10.2 Exhibit 10.2 LUCIRA HEALTH, INC. STOCK OPTION GRANT NOTICE (2014 EQUITY INCENTIVE PLAN) LUCIRA HEALTH, INC. (the “Company”), pursuant to its 2014 Equity Incentive Plan (the “Plan”), hereby grants to Optionholder an option to purchase the number of shares of the Company’s Common Stock set forth below. This option is subject to all of the terms and conditions as set forth in this notice, in
January 15, 2021	EX-10.5	Lucira Health, Inc. 2021 Officer Severance Benefit Plan. EX-10.5 Exhibit 10.5 LUCIRA HEALTH, INC. OFFICER SEVERANCE BENEFIT PLAN APPROVED BY THE BOARD OF DIRECTORS: JANUARY 12, 2021 Section 1. INTRODUCTION. The Lucira Health, Inc. Officer Severance Benefit Plan (the “Plan”) is hereby established effective upon the date of approval by the Board of Directors of Lucira Health, Inc. (the “Company”) set forth above (the “Effective Date”). The purpose of the
January 15, 2021	EX-10.9	Lucira Health, Inc. 2021 Non-Employee Director Compensation Policy. EX-10.9 Exhibit 10.9 NON-EMPLOYEE DIRECTOR COMPENSATION POLICY SUBMITTED TO THE BOARD OF DIRECTORS FOR APPROVAL ON JANUARY 12, 2021 Each member of the Board of Directors (the “Board”) of Lucira Health, Inc. (the “Company”) who is a non-employee director of the Company (each such member, a “Non-Employee Director”) will receive the compensation described in this Non-Employee Director Compensation Po
January 15, 2021	EX-10.3	Lucira Health, Inc. 2021 Employee Cash Incentive Plan. EX-10.3 Exhibit 10.3 LUCIRA HEALTH, INC. EMPLOYEE CASH INCENTIVE PLAN Adopted by the Board of Directors on January 12, 2021 1. Purposes of the Plan. The Plan is intended to increase shareholder value and the success of the Company by motivating Employees to (a) perform to the best of their abilities, and (b) achieve the Company’s performance objectives though the granting of Performance Awards tha
January 15, 2021	EX-10.17	Amended and Restated Employment Agreement, dated as of January 14, 2021, by and between the registrant and Daniel George. EX-10.17 Exhibit 10.17 LUCIRA HEALTH, INC. January 13, 2021 Daniel George Lucira Health, Inc. 1412 62nd Street Emeryville, CA 94608 Re: Amended and Restated Employment Agreement Dear Daniel: You are currently employed by LUCIRA HEALTH, INC. (the “Company”) under the terms of an offer letter between you and the Company dated July 30, 2020 (the “Offer Letter”). The Company is amending and restating
January 15, 2021	EX-10.15	Amended and Restated Employment Agreement, dated as of January 14, 2021, by and between the registrant and Debkishore Mitra. EX-10.15 Exhibit 10.15 LUCIRA HEALTH, INC. January 13, 2021 Debkishore Mitra, Ph.D. Lucira Health, Inc. 1412 62nd Street Emeryville, CA 94608 Re: Amended and Restated Employment Agreement Dear Debkishore: You are currently employed by LUCIRA HEALTH, INC. (the “Company”) under the terms of an offer letter between you and the Company dated August 10, 2013 (the “Offer Letter”). The Company is amendin
January 15, 2021	EX-10.1	Lucira Health, Inc. 2014 Equity Incentive Plan, as amended. EX-10.1 Exhibit 10.1 LUCIRA HEALTH, INC. 2014 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: July 14, 2014 APPROVED BY THE STOCKHOLDERS: July 14, 2014 AMENDED BY THE BOARD OF DIRECTORS: October 2, 2015 AMENDED BY THE STOCKHOLDERS: October 7, 2015 AMENDED BY THE BOARD OF DIRECTORS: March 6, 2019 AMENDED BY THE STOCKHOLDERS: March 6, 2019 AMENDED BY THE BOARD OF DIRECTORS: September 17, 20
January 15, 2021	EX-10.13	Patent License Agreement, dated July 15, 2020, by and between the registrant and Eiken Chemical Co., Ltd. EX-10.13 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [****], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Exhibit 10.13 PATENT LICENSE AGREEMENT THIS PATENT LICENSE AGREEMENT (this “Agreement”), dated as of this 15th day of July, 2020 (the “Effective Date”), by and between Eiken Chemical Co., Ltd., a
December 23, 2020	EX-4.2	LUCIRA HEALTH, INC. AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT Exhibit 4.2 LUCIRA HEALTH, INC. AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT THIS AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (this ?Agreement?), is made as of the 7th day of August, 2020, by and among Lucira Health, Inc., a Delaware corporation (the ?Company?), each of the investors listed on SCHEDULE A hereto, each of which is referred to in this Agreement as an ?Investor?, and any Addition
December 23, 2020	DRS/A	- Table of Contents As confidentially submitted to the U.S. Securities and Exchange Commission on December 23, 2020. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Lucira Health, Inc. (Exact name of registrant as specified in its charter) Delaware 2835 27-2491037 (State or other jurisdicti
December 23, 2020	DRSLTR	- Josh Seidenfeld +1 650 843 5862 [email protected] December 23, 2020 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Eric Atallah Angela Connell Courtney Lindsay Mary Beth Breslin Re: Lucira Health, Inc. Draft Registration Statement on Form S-1 Submitted November 20, 2020 CIK No. 0001652724 Ladies and Gentlemen: On behalf
November 23, 2020	EX-10.12	PATENT LICENSE AGREEMENT CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [****], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
November 23, 2020	EX-10.1	LUCIRA HEALTH, INC. 2014 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: July 14, 2014 APPROVED BY THE STOCKHOLDERS: July 14, 2014 AMENDED BY THE BOARD OF DIRECTORS: October 2, 2015 AMENDED BY THE STOCKHOLDERS: October 7, 2015 AMENDED BY THE Exhibit 10.1 LUCIRA HEALTH, INC. 2014 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: July 14, 2014 APPROVED BY THE STOCKHOLDERS: July 14, 2014 AMENDED BY THE BOARD OF DIRECTORS: October 2, 2015 AMENDED BY THE STOCKHOLDERS: October 7, 2015 AMENDED BY THE BOARD OF DIRECTORS: March 6, 2019 AMENDED BY THE STOCKHOLDERS: March 6, 2019 AMENDED BY THE BOARD OF DIRECTORS: September 17, 2019 AMEND
November 23, 2020	EX-3.3	AMENDED AND RESTATED BYLAWS LUCIRA HEALTH, INC. (A DELAWARE CORPORATION) ARTICLE I Exhibit 3.3 AMENDED AND RESTATED BYLAWS OF LUCIRA HEALTH, INC. (A DELAWARE CORPORATION) ARTICLE I OFFICES Section 1. Registered Office. The registered office of the corporation in the State of Delaware shall be 1209 Orange Street, City of Wilmington, County of New Castle, 19801. Section 2. Other Offices. The corporation shall also have and maintain an office or principal place of business at such
November 23, 2020	EX-10.2	LUCIRA HEALTH, INC. STOCK OPTION GRANT NOTICE (2014 EQUITY INCENTIVE PLAN) Exhibit 10.2 LUCIRA HEALTH, INC. STOCK OPTION GRANT NOTICE (2014 EQUITY INCENTIVE PLAN) LUCIRA HEALTH, INC. (the ?Company?), pursuant to its 2014 Equity Incentive Plan (the ?Plan?), hereby grants to Optionholder an option to purchase the number of shares of the Company?s Common Stock set forth below. This option is subject to all of the terms and conditions as set forth in this notice, in the Opti
November 23, 2020	EX-10.10	LEASE HOLLIS GENERAL PARTNERSHIP (LANDLORD) DIASSESS, INC. (TENANT) HOLLIS GENERAL PROJECT Emeryville, California Exhibit 10.10 LEASE BETWEEN HOLLIS GENERAL PARTNERSHIP (LANDLORD) AND DIASSESS, INC. (TENANT) HOLLIS GENERAL PROJECT Emeryville, California OFFICE LEASE ARTICLE 1 BASIC LEASE PROVISIONS 1.1 BASIC LEASE PROVISIONS In the event of any conflict between these Basic Lease Provisions and any other Lease provision, such other Lease provision shall control. (1) BUILDING AND ADDRESS: 1412 62nd Street (a po
November 23, 2020	EX-3.1	FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION LUCIRA HEALTH, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Exhibit 3.1 FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF LUCIRA HEALTH, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Lucira Health, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the ?General Corporation Law?), DOES HEREBY CERTIFY: 1. That the
November 23, 2020	EX-10.11	MANUFACTURING SERVICES AGREEMENT JABIL INC., LUCIRA HEALTH INC. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [****], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
November 23, 2020	EX-4.1	INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE Exhibit 4.1 LH INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE CUSIP XXXXXX XX X SEE REVERSE FOR CERTAIN DEFINITIONS AND LEGENDS This certifies that is the record holder of FULLY PAID AND NONASSESSABLE SHARES OF COMMON STOCK, $0.001 PAR VALUE PER SHARE, OF Lucira Health, Inc. transferable on the books of the Corporation in person or by duly authorized attorney upon surrender of this Certifica
November 23, 2020	DRS	- Table of Contents As confidentially submitted to the U.S. Securities and Exchange Commission on November 20, 2020. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Lucira Health, Inc. (Exact name of registrant as specified in its charter) Delaware 2835 27-2491037 (State or other jurisdicti

LHDX / Lucira Health Inc - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)